发明名称 |
Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
摘要 |
The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases. |
申请公布号 |
US9376439(B2) |
申请公布日期 |
2016.06.28 |
申请号 |
US201414270915 |
申请日期 |
2014.05.06 |
申请人 |
Incyte Corporation;Incyte Holdings Corporation |
发明人 |
Rodgers James D.;Li Hui-Yin |
分类号 |
A61K31/519;A61P35/00;A61P35/02;A61P35/04;C07D487/04 |
主分类号 |
A61K31/519 |
代理机构 |
Lathrop & Gage LLP |
代理人 |
Lathrop & Gage LLP ;Trinque Brian C. |
主权项 |
1. A method of treating a cancer selected from the group consisting of breast cancer, Castleman's disease, pancreatic cancer, and leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt, wherein said treating refers to ameliorating or inhibiting the disease in a patient. |
地址 |
Wilmington DE US |